Myeloid and lymphoid neoplasms with aberrant FGFR1 activities have been classified into a distinct disease group in haematological neoplasms by the World Health Organization in 2008 [51]. This evidence concerns the gene FGFR1 and hematopoietic and lymphoid cell neoplasm.